文献速递中医内科中药与中成药合理使用

中药复方改善免疫功能治疗Graves病的系统评价与网络药理学研究

Efficacy and safety evaluation of traditional Chinese medicine formulations in treating graves' disease by improving immune function: A systematic review and meta-analysis.
PubMed 文献 · J Ethnopharmacol · 2026-04-08

该系统评价与Meta分析纳入44项RCT,比较中药复方与常规西药治疗Graves病的疗效与安全性。结果显示中药组中医证候积分降低、有效率提高、甲状腺功能及免疫指标有不同程度改善,不良反应发生率低于西药组。网络药理学筛选出6味核心中药及195个共同靶点,涉及PI3K-Akt、MAPK、HIF-1等免疫相关通路。

要点

  • 中药复方可能降低Graves病中医证候积分并提高治疗有效率。
  • 中药复方组不良反应发生率低于常规西药组。
  • 核心中药涉及PI3K-Akt、MAPK、HIF-1等免疫相关通路。

核心结论

  • 中药复方可能有效改善免疫功能并治疗Graves病,但仍需更多高质量RCT与机制研究证实。

研究设计与样本

  • 系统评价与Meta分析纳入44项RCT,比较中药复方与常规西药治疗Graves病,检索8个数据库至2025年8月。
  • 随后采用聚类分析与网络药理学方法筛选核心中药并分析潜在活性成分、靶点与通路。

主要发现

  • 中药组中医证候积分降低(SMD=-1.48,95%CI:-1.89至-1.08,P=0.000)。
  • 中药组有效率提高(RR=1.18,95%CI:1.11至1.24,P=0.000;I2=60.6%)。
  • 中药组不良反应发生率低于西药组(RR=0.35,95%CI:0.28至0.44,P=0.000;I2=18.8%)。
  • 甲状腺功能相关指标与免疫系统相关指标均有不同程度改善。
  • 筛选出6味高频核心中药:夏枯草、地黄、玄参、浙贝母、柴胡、白芍,与Graves病共有195个共同靶点。

关键数值与推荐

  • 中医证候积分SMD=-1.48(95%CI:-1.89至-1.08,P=0.000)。
  • 有效率RR=1.18(95%CI:1.11至1.24,P=0.000;I2=60.6%)。
  • 不良反应发生率RR=0.35(95%CI:0.28至0.44,P=0.000;I2=18.8%)。
  • KEGG通路分析显示PI3K-Akt、MAPK、HIF-1信号通路与免疫功能密切相关。

临床怎么用

  • 在常规西药基础上可考虑联合中药复方以改善Graves病中医证候与免疫指标。
  • 关注夏枯草、地黄、玄参、浙贝母、柴胡、白芍等核心中药的配伍使用。
  • 中药复方可能降低不良反应风险,但需结合患者个体情况辨证使用。

局限性

  • 仍需更多高质量随机对照试验与机制研究确认上述发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: As a common cause of thyrotoxicosis, Graves' disease (GD) has shown potential therapeutic advantages when treated with Traditional Chinese Medicine (TCM). Immune dysfunction serves as a pathological basis of GD, and TCM formulations may regulate abnormal immune status; however, robust evidence-based support and clearly defined pharmacological mechanisms are still lacking. AIM OF THE STUDY: Therefore, this study aims to employ meta-analysis and network pharmacology methods to confirm the therapeutic effects of TCM compound prescriptions on thyroid function and related immune functions, and to explore the potential mechanisms of TCM in treating GD. MATERIALS AND METHODS: A systematic review and meta-analysis were performed focusing on RCTs that examined the efficacy of Chinese herbal compound prescriptions for the treatment of Graves' disease. The studies were collected from eight major electronic databases: the Cochrane Library, PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure (CNKI), Sinomed, Wanfang Database, and the VIP Information-Chinese Scientific Journal Database. The search included publications available up to August 2025. Outcomes assessed included TCM syndrome scores, thyroid function-related indicators, immune-related indicators, and adverse reactions associated with Chinese herbal treatments. After conducting the systematic review and meta-analysis, we utilized cluster analysis and network pharmacology methods to pinpoint the essential herbs within Chinese herbal formulas. The potential bioactive constituents, related targets, and pathways of these core herbs were subsequently analyzed. RESULTS: In total, 44 RCTs were included to compare with the group receiving conventional Western medical treatment. The TCM group demonstrated a reduction in TCM syndrome scores (SMD = -1.48, 95% CI: -1.89 to -1.08, P = 0.000), an increased response rate (RR: 1.18, 95% CI: 1.11 to 1.24, P = 0.000; I2 = 60.6%), and varying degrees of improvement in both thyroid function-related indices and immune system-related indices. The incidence of adverse reactions under TCM compound treatment was lower than that in the Western medicine group (RR: 0.35, 95% CI: 0.28-0.44, P = 0.000; I2 = 18.8%). Furthermore, six core herbal medicines with the highest frequency of use were identified from the employed TCM formulas: Prunella vulgaris L., Rehmannia glutinosa Libosch., Radix Scrophularia, Fritillariae Thunbergii Bulbus, Bupleurum chinense DC. and Paeonia lactiflora Pall. Ultimately, 195 common targets were identified between these six core herbs and Graves' disease. The KEGG pathway analysis demonstrated that various pathways, such as the PI3K-Akt, MAPK, and HIF-1 signaling pathways, are closely associated with immune function. CONCLUSION: TCM compound prescriptions may be effective in improving immune function and treating Graves' disease. Nevertheless, additional high-quality randomized controlled trials and mechanistic studies are necessary to confirm these findings.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li SS, Chen SW, Gan D, et al. Efficacy and safety evaluation of traditional Chinese medicine formulations in treating graves' disease by improving immune function: A systematic review and meta-analysis. J Ethnopharmacol. 2026. PMID: 41956233. doi:10.1016/j.jep.2026.121643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。